IL30165A - Multi-layered medicinal tablets - Google Patents
Multi-layered medicinal tabletsInfo
- Publication number
- IL30165A IL30165A IL30165A IL3016568A IL30165A IL 30165 A IL30165 A IL 30165A IL 30165 A IL30165 A IL 30165A IL 3016568 A IL3016568 A IL 3016568A IL 30165 A IL30165 A IL 30165A
- Authority
- IL
- Israel
- Prior art keywords
- nucleus
- active ingredient
- retarding
- ingredient
- tablet
- Prior art date
Links
- 239000004615 ingredient Substances 0.000 claims description 19
- 230000000979 retarding effect Effects 0.000 claims description 19
- 239000011248 coating agent Substances 0.000 claims description 13
- 238000000576 coating method Methods 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 12
- 235000021355 Stearic acid Nutrition 0.000 claims description 10
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 10
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 10
- 239000008117 stearic acid Substances 0.000 claims description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- UOTMYNBWXDUBNX-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinolin-2-ium;chloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 UOTMYNBWXDUBNX-UHFFFAOYSA-N 0.000 claims description 5
- 238000007906 compression Methods 0.000 claims description 5
- 230000006835 compression Effects 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 229960003207 papaverine hydrochloride Drugs 0.000 claims description 5
- FPEWXTXBURZCKT-VVSTWUKXSA-N 5,7-dihydroxy-2-[3-hydroxy-4-(2-morpholin-4-ylethoxy)phenyl]-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(OCCN3CCOCC3)=CC=2)=O)O1 FPEWXTXBURZCKT-VVSTWUKXSA-N 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 239000004203 carnauba wax Substances 0.000 claims description 3
- 235000013869 carnauba wax Nutrition 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229940045860 white wax Drugs 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 description 18
- 239000000203 mixture Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000000454 talc Substances 0.000 description 10
- 229910052623 talc Inorganic materials 0.000 description 10
- 244000239659 Eucalyptus pulverulenta Species 0.000 description 9
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 8
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- -1 wlt ewax Substances 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 238000005266 casting Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229960002380 dibutyl phthalate Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000012178 vegetable wax Substances 0.000 description 2
- 210000002268 wool Anatomy 0.000 description 2
- OXLXSOPFNVKUMU-UHFFFAOYSA-N 1,4-dioctoxy-1,4-dioxobutane-2-sulfonic acid Chemical compound CCCCCCCCOC(=O)CC(S(O)(=O)=O)C(=O)OCCCCCCCC OXLXSOPFNVKUMU-UHFFFAOYSA-N 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- UJMBCXLDXJUMFB-GLCFPVLVSA-K tartrazine Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-GLCFPVLVSA-K 0.000 description 1
- 239000004149 tartrazine Substances 0.000 description 1
- 229960000943 tartrazine Drugs 0.000 description 1
- 235000012756 tartrazine Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B41/00—After-treatment of mortars, concrete, artificial stone or ceramics; Treatment of natural stone
- C04B41/45—Coating or impregnating, e.g. injection in masonry, partial coating of green or fired ceramics, organic coating compositions for adhering together two concrete elements
- C04B41/50—Coating or impregnating, e.g. injection in masonry, partial coating of green or fired ceramics, organic coating compositions for adhering together two concrete elements with inorganic materials
- C04B41/5025—Coating or impregnating, e.g. injection in masonry, partial coating of green or fired ceramics, organic coating compositions for adhering together two concrete elements with inorganic materials with ceramic materials
- C04B41/5042—Zirconium oxides or zirconates; Hafnium oxides or hafnates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ceramic Engineering (AREA)
- Materials Engineering (AREA)
- Life Sciences & Earth Sciences (AREA)
- Structural Engineering (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR110534A FR1545612A (fr) | 1967-06-15 | 1967-06-15 | Procédé de fabrication de comprimés |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL30165A0 IL30165A0 (en) | 1968-08-22 |
| IL30165A true IL30165A (en) | 1973-04-30 |
Family
ID=8633106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL30165A IL30165A (en) | 1967-06-15 | 1968-06-12 | Multi-layered medicinal tablets |
Country Status (10)
| Country | Link |
|---|---|
| BE (1) | BE716530A (enrdf_load_stackoverflow) |
| DE (1) | DE1767765A1 (enrdf_load_stackoverflow) |
| ES (1) | ES355054A1 (enrdf_load_stackoverflow) |
| FR (1) | FR1545612A (enrdf_load_stackoverflow) |
| GB (1) | GB1233055A (enrdf_load_stackoverflow) |
| IL (1) | IL30165A (enrdf_load_stackoverflow) |
| IT (1) | IT954035B (enrdf_load_stackoverflow) |
| LU (1) | LU56264A1 (enrdf_load_stackoverflow) |
| NL (1) | NL151902B (enrdf_load_stackoverflow) |
| SU (1) | SU458966A3 (enrdf_load_stackoverflow) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5138412A (en) * | 1974-09-24 | 1976-03-31 | Nippon Kayaku Kk | Kokoseizai no seiho |
| US4076804A (en) * | 1975-07-18 | 1978-02-28 | Abbott Laboratories | Erythromycin therapy |
| SE418247B (sv) * | 1975-11-17 | 1981-05-18 | Haessle Ab | Sett att framstella kroppar med reglerad frigoring av en aktiv komponent |
| US4704284A (en) * | 1982-08-12 | 1987-11-03 | Pfizer Inc. | Long-acting matrix tablet formulations |
| US4503031A (en) * | 1982-12-17 | 1985-03-05 | Glassman Jacob A | Super-fast-starting-sustained release tablet |
| DK62184D0 (da) * | 1984-02-10 | 1984-02-10 | Benzon As Alfred | Diffusionsovertrukket polydepotpraeparat |
| US5032406A (en) * | 1989-02-21 | 1991-07-16 | Norwich Eaton Pharmaceuticals, Inc. | Dual-action tablet |
| US5213807A (en) * | 1990-05-03 | 1993-05-25 | Chemburkar Pramod B | Pharmaceutical composition containing ibuprofen and a prostaglandin |
| EP1836665B1 (en) | 2004-11-19 | 2013-01-16 | GlaxoSmithKline LLC | Method for customized dispensing of variable dose drug combination products for individualizing of therapies |
-
1967
- 1967-06-15 FR FR110534A patent/FR1545612A/fr not_active Expired
-
1968
- 1968-06-12 IL IL30165A patent/IL30165A/en unknown
- 1968-06-13 LU LU56264A patent/LU56264A1/xx unknown
- 1968-06-13 NL NL686808312A patent/NL151902B/xx unknown
- 1968-06-13 BE BE716530D patent/BE716530A/xx unknown
- 1968-06-14 GB GB1233055D patent/GB1233055A/en not_active Expired
- 1968-06-14 DE DE19681767765 patent/DE1767765A1/de active Pending
- 1968-06-14 IT IT52034/68A patent/IT954035B/it active
- 1968-06-14 SU SU1247008A patent/SU458966A3/ru active
- 1968-06-15 ES ES355054A patent/ES355054A1/es not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| DE1767765A1 (de) | 1972-03-30 |
| ES355054A1 (es) | 1969-11-16 |
| LU56264A1 (enrdf_load_stackoverflow) | 1968-09-23 |
| NL151902B (nl) | 1977-01-17 |
| IT954035B (it) | 1973-08-30 |
| NL6808312A (enrdf_load_stackoverflow) | 1968-12-16 |
| IL30165A0 (en) | 1968-08-22 |
| FR1545612A (fr) | 1968-11-15 |
| SU458966A3 (ru) | 1975-01-30 |
| GB1233055A (enrdf_load_stackoverflow) | 1971-05-26 |
| BE716530A (enrdf_load_stackoverflow) | 1968-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3115441A (en) | Timed release pharmaceutical preparations and method of making the same | |
| US5283065A (en) | Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form | |
| US20180008539A1 (en) | Gastroretentive extended release suspension compositions | |
| US5260072A (en) | Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets | |
| US4851226A (en) | Chewable medicament tablet containing means for taste masking | |
| KR100258223B1 (ko) | 신속 용해형 정제 및 그의 제조법 | |
| US4415547A (en) | Sustained-release pharmaceutical tablet and process for preparation thereof | |
| EP2893940B1 (en) | Granulated material for tablet that rapidly disintegrates in mouth | |
| GB2101484A (en) | Oral dipyridamole compositions | |
| AU765977B2 (en) | Pharmaceutical combination preparations | |
| IE59158B1 (en) | Method for production of stable nicorandil preparation | |
| US6274168B1 (en) | Phenytoin sodium pharmaceutical compositions | |
| KR970007899B1 (ko) | 맛 은폐를 위한 수단을 포함하는 저작가능한 의약 정제 | |
| MX2011001487A (es) | Uso de sucralosa como agente granulante. | |
| KR20000076475A (ko) | 약제학적 활성 성분의 함량이 90중량% 이하인 펠렛의제조방법 | |
| US5422122A (en) | Controlled release potassium chloride tablet | |
| US5460825A (en) | Taste mask coatings for preparing chewable pharmaceutical tablets | |
| IL30165A (en) | Multi-layered medicinal tablets | |
| EP0473431B1 (en) | Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets | |
| US4601895A (en) | Delayed-action acetylsalicylic acid formulations for oral administration | |
| EP0538034B1 (en) | Taste mask coatings for preparing chewable pharmaceutical tablets | |
| CN102137664B (zh) | 具有被边界隔开的有效成分的固体药物制剂 | |
| EP2549982A1 (en) | Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe | |
| RU2326660C1 (ru) | Пероральный лекарственный препарат мемантин (варианты) и способ его получения (варианты) | |
| JP2002530315A (ja) | 植物抽出物由来の固形剤型医薬品を製造する方法 |